Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|June 5, 2009
Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximabIvana Ilić, Zdravko Mitrović, Igor Aurer, et al.
Clinical Lymphoma & Myeloma|May 2, 2009
CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphomaZdravko Mitrovic, Ivana Ilic, Marin Nola, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|December 11, 2019
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera<sup>®</sup>) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)Jeff P Sharman, Anna Marina Liberati, Kenichi Ishizawa, et al.
Internal Medicine Journal|October 26, 2017
High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisoloneSandra Basic-Kinda, Ivan Karlak, Nadira Durakovic, et al.
Collegium Antropologicum|May 4, 2010
FNA based diagnosis of head and neck nodal lymphomaKoraljka Gjadrov Kuvezdić, Igor Aurer, Suncica Ries, et al.
Lijecnicki Vjesnik|November 8, 2006
[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]Igor Aurer, Drazen Huić, Marijan Zuvić, et al.
Healthcare (Basel, Switzerland)|September 23, 2022
Tackling Mantle Cell Lymphoma in EuropeDenis Horgan, Jan Walewski, Igor Aurer, et al.
Acta Clinica Croatica|August 29, 2014
Simultaneous presentation of oral and skin anaplastic large T-cell lymphomaAleksandar Milenović, Vanja Vucićević Boras, Ivana Ilić, et al.
Lijecnicki Vjesnik|May 16, 2013
[Lymphoma diagnosis and treatment - second Croatian consensus]Igor Aurer, Slavko Gasparov, Marko Kralik, et al.
Croatian Medical Journal|October 29, 2002
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective studyIgor Aurer, Nadira Duraković, Ivo Radman, et al.
Pageof 7